Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J, Strych U, Chen WH, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, Poveda C, Jose Villar M, Rani Thimmiraju S, Lopez B, Gillespie PM, Ronca S, Kimata JT, Reers M, Paradkar V, Hotez PJ, Elena Bottazzi M. Pollet J, et al. Among authors: paradkar v. Vaccine. 2022 Jun 9;40(26):3655-3663. doi: 10.1016/j.vaccine.2022.05.007. Epub 2022 May 8. Vaccine. 2022. PMID: 35568591 Free PMC article.
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, Kyasani M, Manoharan SK, Medigeshi G, Singh J, Shaman H, Singh C, Rao A V. Thuluva S, et al. Among authors: paradkar v. EBioMedicine. 2022 Sep;83:104217. doi: 10.1016/j.ebiom.2022.104217. Epub 2022 Aug 12. EBioMedicine. 2022. PMID: 35970020 Free PMC article. Clinical Trial.
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Narang M, Nanjappa P, Mahantshetti N, Swarup Garg B, Pandey AK. Thuluva S, et al. Among authors: paradkar v. Vaccine. 2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31. Vaccine. 2022. PMID: 36328879 Clinical Trial.
Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development.
Looney MM, Hatherill M, Musvosvi M, Flynn J, Kagina BM, Frick M, Kafuko Z, Schmidt A, Southern J, Wilder-Smith A, Tippoo P, Paradkar V, Popadić D, Scriba TJ, Hanekom W, Giersing B. Looney MM, et al. Among authors: paradkar v. Vaccine. 2023 Nov 22;41(48):7060-7066. doi: 10.1016/j.vaccine.2023.10.026. Epub 2023 Oct 21. Vaccine. 2023. PMID: 37872013 Free article.
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator.
Thuluva S, Paradkar V, Matur R, Turaga K, Gv SR. Thuluva S, et al. Among authors: paradkar v. Hum Vaccin Immunother. 2022 Nov 30;18(5):2043103. doi: 10.1080/21645515.2022.2043103. Epub 2022 Mar 25. Hum Vaccin Immunother. 2022. PMID: 35333702 Free PMC article. Clinical Trial.
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Singh C, Rao A V, Basu I, Kumar KAA, Pandey AK. Thuluva S, et al. Among authors: paradkar v. Hum Vaccin Immunother. 2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37113012 Free PMC article. Clinical Trial.
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J, Strych U, Chen WH, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, Poveda C, Villar MJ, Thimmiraju SR, Lopez B, Gillespie PM, Ronca S, Kimata JT, Reers M, Paradkar V, Hotez P, Bottazzi ME. Pollet J, et al. Among authors: paradkar v. bioRxiv [Preprint]. 2022 Mar 22:2021.07.06.451353. doi: 10.1101/2021.07.06.451353. bioRxiv. 2022. PMID: 34268512 Free PMC article. Updated. Preprint.
Novel pyrrolidine heterocycles as CCR1 antagonists.
Merritt JR, James R, Paradkar VM, Zhang C, Liu R, Liu J, Jacob B, Chiriac C, Ohlmeyer MJ, Quadros E, Wines P, Postelnek J, Hicks CM, Chen W, Kimble EF, O'Brien L, White N, Desai H, Appell KC, Webb ML. Merritt JR, et al. Among authors: paradkar vm. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5477-9. doi: 10.1016/j.bmcl.2010.07.082. Epub 2010 Jul 24. Bioorg Med Chem Lett. 2010. PMID: 20708929
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.
Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann T, Hruza A, Madison V, Nomeir AA, Wang Y, Kirschmeier P, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ. Paruch K, et al. Among authors: paradkar vm. ACS Med Chem Lett. 2010 May 17;1(5):204-8. doi: 10.1021/ml100051d. eCollection 2010 Aug 12. ACS Med Chem Lett. 2010. PMID: 24900195 Free PMC article.
22 results